In a drug screening study using ovalbumin-specific systems, EGFR TKI, especially afatinib, could enhance the efficacy of anti-PD-1 by improving MHC expression and decreasing PD-L1 expression in tumor cells [16]. The gene discussed is HLA-C; the disease is neoplasm.